LINCOLN PHARMACEUTICALS
|
|
BOM : 531633     NSE : LINCOLN     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Average [Stock is fairly valued] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : None or < 25% |
Feb 08,2023 |
Price(EOD): ₹ 322.30
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 644.60 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
LINCOLN PHARMACEUTICALS | 2.1% | -5.4% | -12.4% |
SUN PHARMACEUTICAL INDUSTRIES | 0.5% | -0.1% | 12.5% |
DIVIS LABORATORIES | -14.3% | -19.1% | -36.2% |
CIPLA | 1.4% | -4.4% | 9% |
DR REDDYS LABORATORIES | 2.7% | 3.5% | 2.1% |
TORRENT PHARMACEUTICALS | 1% | -0.4% | 14.4% |
ABBOTT INDIA | 3.8% | -4.4% | 32% |
ZYDUS LIFESCIENCES | 9.6% | 7% | 17.2% |
ALKEM LABORATORIES | 3.4% | 4.1% | -12.8% |
FUNDAMENTAL ANALYSIS OF LINCOLN PHARMACEUTICALS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF LINCOLN PHARMACEUTICALS
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
9.59
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 67.35 Cr
[Latest Qtr - Sep2022 - Consolidated Results ] 1.49
P/B Calculated based on Book Value of Rs 432.88 Cr
[Latest Year - Mar2022 - Consolidated Results ] 1.33
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 486.55 Cr
[Latest Qtr - Sep2022 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
-3% -4% 4% |
SHARE PRICE MOMENTUM OF LINCOLN PHARMACEUTICALS
LINCOLN PHARMACEUTICALS vs SENSEX
DEBT OF LINCOLN PHARMACEUTICALS
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2022 2021 2020 Avg_3yrs |
0 0 0.02 0.01 |
0 0 0.02 0.01 |
[Last Annual Data : Mar2022]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF LINCOLN PHARMACEUTICALS
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2022 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF LINCOLN PHARMACEUTICALS
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
13.88% 70.89% 53.21% 57.95% |
10.31% -1.27% 4.99% 2.97% |
QtrlyTrend |
6 | |
Latest Qtr: Sep2022 | ||
Quarterly Result Analysis → |
LINCOLN PHARMACEUTICALS related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE MIDSMALLCAP | 1.5% | -1.6% | -3.1% |
S&P BSE ALLCAP | 1.2% | -1.8% | -0.8% |
S&P BSE SMALL CAP | 1% | -2.1% | -5.6% |
S&P BSE HEALTHCARE | 0.3% | -2.3% | -9.3% |
You may also like the below Video Courses
FAQ about LINCOLN PHARMACEUTICALS
Is LINCOLN PHARMACEUTICALS good for long term investment?
As on Feb 08,2023, the Fundamentals of LINCOLN PHARMACEUTICALS look Strong and hence it may be good for long term investment! See Financial Performance of LINCOLN PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is LINCOLN PHARMACEUTICALS UnderValued or OverValued?
As on Feb 08,2023, LINCOLN PHARMACEUTICALS is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!What is the Intrinsic Value of LINCOLN PHARMACEUTICALS ?
As on Feb 08,2023, the Intrinsic Value of LINCOLN PHARMACEUTICALS is Rs. 333.06 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 333.06
Fair Value [Median EV / Sales Model] : Rs. 337.10
Fair Value [Median Price / Sales Model] : Rs. 309.25
Estimated Median Fair Value of LINCOLN PHARMACEUTICALS : Rs. 333.06
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
Is LINCOLN PHARMACEUTICALS trading at a Premium or Discount?
As on Feb 08,2023, LINCOLN PHARMACEUTICALS is trading at a Discount of -3% based on the estimates of Median Intrinsic Value!